N
SPRY icon

Nuveen’s ARS Pharmaceuticals SPRY Stock Holding History

Nuveen’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Buy
150,696
+1,099
+0.7% +$10.5K ﹤0.01% 2494
2025
Q4 		$1.74M Hold
149,597
– – ﹤0.01% 2345
2025
Q3 		$1.5M Buy
149,597
+10,464
+8% +$150K ﹤0.01% 2423
2025
Q2 		$2.43M Sell
139,133
-15,323
-10% -$221K ﹤0.01% 2220
2025
Q1 		$1.94M Sell
154,456
-3,495
-2% -$42.1K ﹤0.01% 2347
2024
Q4 		$1.67M Hold
157,951
– – ﹤0.01% 2457
2024
Q3 		$2.29M Buy
157,951
+3,517
+2% +$41.8K ﹤0.01% 2344
2024
Q2 		$1.31M Buy
154,434
+56,839
+58% +$504K ﹤0.01% 2589
2024
Q1 		$997K Hold
97,595
– – ﹤0.01% 2711
2023
Q4 		$535K Sell
97,595
-14,179
-13% -$62.1K ﹤0.01% 2977
2023
Q3 		$423K Buy
111,774
+14,179
+15% +$93.1K ﹤0.01% 2897
2023
Q2 		$654K Buy
+97,595
New +$651K ﹤0.01% 2843
2022
Q2 		– Sell
-64,723
Closed -$272K – 3465
2022
Q1 		$272K Buy
64,723
+1,433
+2% +$6.24K ﹤0.01% 3139
2021
Q4 		$391K Sell
63,290
-12,743
-17% -$104K ﹤0.01% 3128
2021
Q3 		$759K Buy
76,033
+20,042
+36% +$494K ﹤0.01% 3082
2021
Q2 		$1.73M Buy
55,991
+5,741
+11% +$184K ﹤0.01% 2783
2021
Q1 		$2.19M Buy
+50,250
New +$2.38M ﹤0.01% 2576

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Nuveen's SPRY Position: Q1 2026 in Review

Nuveen increased its ARS Pharmaceuticals (SPRY) stake by 0.73% in Q1 2026, buying an estimated $10.5K and bringing the position to 150,696 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2494.

Nuveen first reported a position in SPRY in Q1 2021 and has held it in 17 quarters since. The position peaked at $2.43M in Q2 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Nuveen held 150,696 shares of ARS Pharmaceuticals worth $1.21M as of Q1 2026.
  • Nuveen bought 1,099 ARS Pharmaceuticals shares in Q1 2026, an estimated $10.5K.
  • ARS Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2494 holding.
  • Nuveen first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
  • Nuveen's ARS Pharmaceuticals position peaked at $2.43M in Q2 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.